The Board of Directors' Dividend Proposal to the Annual General Meeting of Biovitrum
The Board of Directors in Biovitrum AB (publ) has decided to propose the Annual General Meeting on May 3rd, that no dividend should be made for the financial year 2006. For additional information, please contact: Biovitrum AB (publ) Anders Martin-Löf, Director Investor Relations Phone: +46 8 697 37 07, cell phone: +46 70 624 32 56 [email protected] Anna Karin Källén, Vice President, Corporate Communications Phone: +46 8 697 20 85, cell phone: +46 73 433 20 85 [email protected] About Biovitrum Biovitrum is one of the largest biopharma companies in Europe. With operations in Sweden and in the UK Biovitrum conducts research and develops pharmaceuticals for unmet medical needs both for common diseases and conditions that affect smaller patient populations. Biovitrum has a broad and balanced R&D portfolio with several projects in clinical and preclinical phases for the treatment of obesity, diabetes, inflammation and eye and blood diseases as well as a number of well defined niche indications. Biovitrum develops and produces protein-based drugs on a contractual basis and markets a range of specialist pharmaceuticals primarily in the Nordic countries. Biovitrum has revenues of approximately SEK 1.2 billion and 550 employees. Biovitrum is listed on the Stockholm Stock Exchange since September 15, 2006. For more information see www.biovitrum.com.
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Every day, we work actively to find better ways to understand and meet patient needs.
Find out more about our business and financial performance.
Here we present our most recent press releases, news articles, and images.